title: Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer.
abstract: This retrospective study aimed to observe the cura-tive effect and adverse reactions of three-dimensional conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent epithelial ovarian carcinoma. The chemoradiotherapy group (N = 22) received 15 mv X-rays with 1.8 to 2.0 Gy/f/d radiation, 5 times per week. The total dose was 45 to 65 Gy; the median dose was 52.5 Gy. Topotecan chemotherapy (2.0 mg/m(2)) was administered after the first week of radiotherapy on days 1, 8, and 15; it was repeated every 28 days. The only che-motherapy group (N = 20) received topotecan chemotherapy (4.0 mg/m(2)) in the first week, and the dose was administered on days 1, 8, and 15; it was repeated every 28 days. The median follow-up times were 18.5 months (2 to 37.7) and 10.8 months (1.5 to 29.6) in the chemoradiotherapy and in the only chemotherapy groups, respectively. The total response rates were 42.1% (8/19) and 11.1% (2/18), respectively. The clinical benefit rates were 68.4% (13/19) and 22.2% (4/18), respectively, with significant difference (P < 0.05). The median disease progression-free periods were 9.8 and 6.6 months, respectively, with significant difference (P < 0.001). The median survival times were 19.7 and 12.5 months, respective-ly, with significant difference (P < 0.05). The degrees of digestive tract reaction rates were 26.3% (5/19) and 16.7% (3/18), whereas the hematology toxicity rates were 21.1% (4/19) and 22.2% (4/18), respectively, with no significant difference (P > 0.05). As three-dimensional conformal radiotherapy combined with topotecan che-motherapy had good curative effect on platinum-resistant recurrent epithelial ovarian cancer, with mild adverse reactions, this tech-nique can be used as a remedial measure.
authors.affiliation: Department of Gynecologic Oncology, Shandong Tumor Hospital and Institute, Jinan, Shandong Province, China.
authors.forename: P
authors.initials: P
authors.lastname: Wei
authors.affiliation: Department of Occupational Health and Occupational Medicine Institute, Jinan, Shandong Province, China.
authors.forename: Z H
authors.initials: ZH
authors.lastname: Zhang
authors.affiliation: Central People's Hospital of Tengzhou City, Jining Medical College, Tengzhou, Shandong Province, China.
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Gynecologic Oncology, Shandong Tumor Hospital and Institute, Jinan, Shandong Province, China.
authors.forename: X L
authors.initials: XL
authors.lastname: Du
authors.affiliation: Oncology Department, Affiliated Hospital of Jining Medical College, Jining, Shandong Province, China.
authors.forename: C P
authors.initials: CP
authors.lastname: Shan
authors.affiliation: Department of Gynecologic Oncology, Shandong Tumor Hospital and Institute, Jinan, Shandong Province, China weiping_wp@yeah.net.
authors.forename: X G
authors.initials: XG
authors.lastname: Sheng
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009375:Neoplasms, Glandular and Epithelial / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D020266:Radiotherapy, Conformal; D012189:Retrospective Studies; D019772:Topotecan / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan; D002945:Cisplatin